AB1010 (Pancreatic Cancer) - Analysis and Forecasts to 2020
Summary
GlobalData’s pharmaceuticals report, “AB1010 (Pancreatic Cancer) - Analysis and Forecasts to 2020” provides AB1010 sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Pancreatic Cancer market.
This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
Reasons to buy
Keywords
Masitinib, AB1010, Pancreatic Cancer, IGF-1R, Sales forecast, mesylate salt, multi-targeted protein tyrosine kinase inhibitor, TKI, phase III, phase 3, pipeline, GVAX, HyperAcute Pancreas, Irinotecan, Sutent, GV1001, Afinitor, Avastin, AMG479, Abraxane, Masitinib, Gemzar, Nexavar, S-1, Tarceva, Certican, AB Science
Summary
GlobalData’s pharmaceuticals report, “AB1010 (Pancreatic Cancer) - Analysis and Forecasts to 2020” provides AB1010 sales forecasts for the US, and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2013-2020). The report also includes information on Pancreatic Cancer market.
This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US and EU5
- Analysis and review of Masitinib including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Masitinib including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts for 2013-2020 for AB1010 in the US and EU5
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Keywords
Masitinib, AB1010, Pancreatic Cancer, IGF-1R, Sales forecast, mesylate salt, multi-targeted protein tyrosine kinase inhibitor, TKI, phase III, phase 3, pipeline, GVAX, HyperAcute Pancreas, Irinotecan, Sutent, GV1001, Afinitor, Avastin, AMG479, Abraxane, Masitinib, Gemzar, Nexavar, S-1, Tarceva, Certican, AB Science
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 INTRODUCTION
2.1 Pancreatic Cancer
2.2 Pancreatic Cancer Market
2.3 Epidemiology
2.4 Etiology
2.5 The Main Recognized Risk Factors
2.5.1 Cigarette Smoking
2.5.2 Age
2.5.3 Gender
2.5.4 Family History
2.5.5 Other Factors
2.5.6 Pancreatic cancer prevention
2.6 GlobalData Report Guidance
3 PANCREATIC CANCER: MARKET CHARACTERIZATION
3.1 Pancreatic Cancer Disease Market
3.2 Pancreatic Cancer Disease Market Forecasts and CAGR
3.3 Drivers for the Pancreatic Cancer Disease Market
3.3.1 High Incidence
3.3.2 Large Unmet Need
3.3.3 Active Pipeline
4 TUMOR-NODE-METASTASES (TNM) CLASSIFICATION OF PANCREATIC CANCER
4.1 Treatment Options in Pancreatic cancer
4.2 Classification of Patients with Pancreatic Cancer
5 AB1010
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Factors Affecting Sales of AB1010
5.4.1 Better Efficacy
5.4.2 Orphan Status in the EU
5.4.3 Future Competition
5.4.4 Commercialization Capabilities of the company
5.5 Drug Evaluation
5.5.1 Drug Risk Benefit Score
5.5.2 Intensity of Competition
5.6 Sales Estimates
5.6.1 Target Patient Pool of AB1010
5.6.2 Dosing
5.6.3 Market Penetration
5.6.4 Annual Cost of Therapy
5.6.5 Sales Forecasts of AB1010
6 APPENDIX
6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to Take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources
LIST OF TABLES
Table 1: Pancreatic cancer, Estimated Incidence and Mortality, 2008–2030
Table 2: Pancreatic Cancer, TNM Classification
Table 3: AB1010, Pancreatic Cancer, Clinical Trial Results
Table 4: AB1010, Pancreatic Cancer, Drug Risk Benefit Score
Table 5: AB1010, Pancreatic Cancer, Global, Sales Forecasts ($m), 2013-2020
Table 6: AB1010, Pancreatic Cancer, The US, Sales Forecasts ($m), 2013-2020
Table 7: AB1010, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2013-2020
Table 8: AB1010, Pancreatic Cancer, France, Sales Forecasts ($m), 2013-2020
Table 9: AB1010, Pancreatic Cancer, Germany, Sales Forecasts ($m), 2013-2020
Table 10: AB1010, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2013-2020
Table 11: AB1010, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2013-2020
LIST OF FIGURES
Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2008
Figure 2: Total number of cigarettes consumed, The US, 1976-2006
Figure 3: Average Incidence Rate per 100,000, Pancreatic Cancer, the US, Both Sexes, 1992–2007
Figure 4: Incidence Rate per 100000, Pancreatic Cancer, the US, Both Sexes, 2010–2030
Figure 5: Pancreatic Cancer, Global, Market Size Forecasts ($m), 2010–2020
Figure 6: Pancreatic Cancer, Worldwide, Incidence (in million), 2008-2030
Figure 7: Oncology, Worldwide, Incidence (in million), 2008-2030
Figure 8: Broad Classification of Pancreatic Cancer
Figure 9: Classification of Patients with Pancreatic Cancer
Figure 10: AB1010, Pancreatic Cancer, Drug Model Diagram
Figure 11: AB1010, Pancreatic Cancer, Global, Sales Forecasts ($m), 2013-2020
Figure 12: AB1010, Pancreatic Cancer, The US, Sales Forecasts ($m), 2013-2020
Figure 13: AB1010, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2013-2020
Figure 14: AB1010, Pancreatic Cancer, France, Sales Forecasts ($m), 2013-2020
Figure 15: AB1010, Pancreatic Cancer, Germany, Sales Forecasts ($m), 2013-2020
Figure 16: AB1010, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2013-2020
Figure 17: AB1010, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2013-2020
Figure 18: AB1010, Pancreatic Cancer, Global, Sales Distribution by Country (%), 2020
Figure 19: Patients Approved for the Drug
1.1 List of Tables
1.2 List of Figures
2 INTRODUCTION
2.1 Pancreatic Cancer
2.2 Pancreatic Cancer Market
2.3 Epidemiology
2.4 Etiology
2.5 The Main Recognized Risk Factors
2.5.1 Cigarette Smoking
2.5.2 Age
2.5.3 Gender
2.5.4 Family History
2.5.5 Other Factors
2.5.6 Pancreatic cancer prevention
2.6 GlobalData Report Guidance
3 PANCREATIC CANCER: MARKET CHARACTERIZATION
3.1 Pancreatic Cancer Disease Market
3.2 Pancreatic Cancer Disease Market Forecasts and CAGR
3.3 Drivers for the Pancreatic Cancer Disease Market
3.3.1 High Incidence
3.3.2 Large Unmet Need
3.3.3 Active Pipeline
4 TUMOR-NODE-METASTASES (TNM) CLASSIFICATION OF PANCREATIC CANCER
4.1 Treatment Options in Pancreatic cancer
4.2 Classification of Patients with Pancreatic Cancer
5 AB1010
5.1 Introduction
5.2 Mechanism of Action
5.3 Clinical Studies
5.4 Factors Affecting Sales of AB1010
5.4.1 Better Efficacy
5.4.2 Orphan Status in the EU
5.4.3 Future Competition
5.4.4 Commercialization Capabilities of the company
5.5 Drug Evaluation
5.5.1 Drug Risk Benefit Score
5.5.2 Intensity of Competition
5.6 Sales Estimates
5.6.1 Target Patient Pool of AB1010
5.6.2 Dosing
5.6.3 Market Penetration
5.6.4 Annual Cost of Therapy
5.6.5 Sales Forecasts of AB1010
6 APPENDIX
6.1 Market Definitions
6.2 Abbreviations
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Forecasting
6.3.4 Number of Patients Approved to Take the Drug
6.3.5 Net Penetration of Drug
6.3.6 Net Annual Dosing
6.3.7 Annual Cost of Therapy
6.4 Drug Sales Estimates Model
6.5 Contact Us
6.6 Disclaimer
6.7 Sources
LIST OF TABLES
Table 1: Pancreatic cancer, Estimated Incidence and Mortality, 2008–2030
Table 2: Pancreatic Cancer, TNM Classification
Table 3: AB1010, Pancreatic Cancer, Clinical Trial Results
Table 4: AB1010, Pancreatic Cancer, Drug Risk Benefit Score
Table 5: AB1010, Pancreatic Cancer, Global, Sales Forecasts ($m), 2013-2020
Table 6: AB1010, Pancreatic Cancer, The US, Sales Forecasts ($m), 2013-2020
Table 7: AB1010, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2013-2020
Table 8: AB1010, Pancreatic Cancer, France, Sales Forecasts ($m), 2013-2020
Table 9: AB1010, Pancreatic Cancer, Germany, Sales Forecasts ($m), 2013-2020
Table 10: AB1010, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2013-2020
Table 11: AB1010, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2013-2020
LIST OF FIGURES
Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2008
Figure 2: Total number of cigarettes consumed, The US, 1976-2006
Figure 3: Average Incidence Rate per 100,000, Pancreatic Cancer, the US, Both Sexes, 1992–2007
Figure 4: Incidence Rate per 100000, Pancreatic Cancer, the US, Both Sexes, 2010–2030
Figure 5: Pancreatic Cancer, Global, Market Size Forecasts ($m), 2010–2020
Figure 6: Pancreatic Cancer, Worldwide, Incidence (in million), 2008-2030
Figure 7: Oncology, Worldwide, Incidence (in million), 2008-2030
Figure 8: Broad Classification of Pancreatic Cancer
Figure 9: Classification of Patients with Pancreatic Cancer
Figure 10: AB1010, Pancreatic Cancer, Drug Model Diagram
Figure 11: AB1010, Pancreatic Cancer, Global, Sales Forecasts ($m), 2013-2020
Figure 12: AB1010, Pancreatic Cancer, The US, Sales Forecasts ($m), 2013-2020
Figure 13: AB1010, Pancreatic Cancer, The UK, Sales Forecasts ($m), 2013-2020
Figure 14: AB1010, Pancreatic Cancer, France, Sales Forecasts ($m), 2013-2020
Figure 15: AB1010, Pancreatic Cancer, Germany, Sales Forecasts ($m), 2013-2020
Figure 16: AB1010, Pancreatic Cancer, Italy, Sales Forecasts ($m), 2013-2020
Figure 17: AB1010, Pancreatic Cancer, Spain, Sales Forecasts ($m), 2013-2020
Figure 18: AB1010, Pancreatic Cancer, Global, Sales Distribution by Country (%), 2020
Figure 19: Patients Approved for the Drug
